Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Solitario Resources
XPL
$73.9M
| $189K | ﹤0.01% |
600,416
+183,386
| +44% | +$49.6K |
|
3177
HBT Financial
HBT
$1.35B
| $188K | ﹤0.01% |
+14,100
| New | +$169K |
|
3178
Peraso
PRSO
$10.3M
| $188K | ﹤0.01% |
2,569
-43
| -2% | -$2.69K |
|
|
REVG
3179
DELISTED
REV Group
REVG
| $188K | ﹤0.01% |
30,800
-7,991
| -21% | -$42.9K |
|
3180
KALA BIO
KALA
$17.9M
| $181K | ﹤0.01% |
7
-40
| -85% | -$1.13M |
|
3181
ClearPoint Neuro
CLPT
$470M
| $180K | ﹤0.01% |
50,600
+22,300
| +79% | +$82.9K |
|
3182
Exicure
XCUR
$8.35M
| $179K | ﹤0.01% |
490
-1,266
| -72% | -$459K |
|
|
CNSY
3183
Cerenome, Inc. Common Stock
CNSY
$25.5M
| $178K | ﹤0.01% |
224
+8
| +4% | +$5.34K |
|
|
HZN
3184
DELISTED
Horizon Global Corporation
HZN
| $178K | ﹤0.01% |
81,002
-1,900
| -2% | -$3.48K |
|
|
SSY
3185
DELISTED
SunLink Health Systems
SSY
| $177K | ﹤0.01% |
197,800
+30,400
| +18% | +$23.9K |
|
3186
Xenetic Biosciences
XBIO
$7.54M
| $177K | ﹤0.01% |
17,320
+908
| +6% | +$8.62K |
|
|
IMMP
3187
Immutep
IMMP
$59.5M
| $176K | ﹤0.01% |
162,639
-174,650
| -52% | -$180K |
|
|
TWAV
3188
TaoWeave Inc
TWAV
$5.16M
| $176K | ﹤0.01% |
197
+67
| +52% | +$46.7K |
|
|
EVLO
3189
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $176K | ﹤0.01% |
1,799
+420
| +30% | +$36.8K |
|
3190
Oragenics
OGEN
$2.39M
| $174K | ﹤0.01% |
+139
| New | +$137K |
|
|
OSN
3191
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $173K | ﹤0.01% |
61,589
-15,317
| -20% | -$33.7K |
|
|
ASXC
3192
DELISTED
Asensus Surgical, Inc.
ASXC
| $172K | ﹤0.01% |
+318,467
| New | +$154K |
|
|
VVUS
3193
DELISTED
Vivus Inc
VVUS
| $169K | ﹤0.01% |
205,341
-211,804
| -51% | -$251K |
|
|
CRESY
3194
Cresud
CRESY
$752M
| $168K | ﹤0.01% |
+59,006
| New | +$189K |
|
3195
Alaunos Therapeutics
TCRT
$4.86M
| $167K | ﹤0.01% |
338
-4,176
| -93% | -$1.86M |
|
|
IRS
3196
IRSA Inversiones y Representaciones
IRS
$1.25B
| $166K | ﹤0.01% |
+53,025
| New | +$183K |
|
|
BKYI
3197
BIO-key International
BKYI
$4.1M
| $164K | ﹤0.01% |
+128
| New | +$152K |
|
|
BCOM
3198
DELISTED
B Communications Ltd
BCOM
| $164K | ﹤0.01% |
82,466
+14,450
| +21% | +$21.7K |
|
3199
Phio Pharmaceuticals
PHIO
$12.7M
| $162K | ﹤0.01% |
687
+306
| +80% | +$73.3K |
|
|
THER
3200
DELISTED
THERATECHNOLOGIES INC COM
THER
| $161K | ﹤0.01% |
80,300
+29,300
| +57% | +$58.7K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.